INTERLEUKIN-2-FC FUSION PROTEINS AND METHODS OF USE

Provided are serum half-life extended-IL-2 variant (IL-2v) heterodimers having reduced binding to the IL2Rα (CD25) subunit. In particular, Fc-IL-2v heterodimers are provided and methods for making and using, e.g. for enhancing an immune response, e.g. in the prevention and treatment of viral infecti...

Full description

Saved in:
Bibliographic Details
Main Authors PAPALIA, Giuseppe, BACA, Manuel, GILMORE, Sarah A, MUKHERJEE, Prasenjit K, TAM, Danny W, JAVANBAKHT, Hassan, HUNG, Magdeleine S, KHAN, Shahzada, THOMAS, Majlinda K, KANWAR, Manu, NAGEL, Mark R
Format Patent
LanguageEnglish
French
Published 28.04.2022
Subjects
CHEMISTRY
METALLURGY
ORGANIC CHEMISTRY
PEPTIDES
Online AccessGet full text

Cover

More Information
Summary:Provided are serum half-life extended-IL-2 variant (IL-2v) heterodimers having reduced binding to the IL2Rα (CD25) subunit. In particular, Fc-IL-2v heterodimers are provided and methods for making and using, e.g. for enhancing an immune response, e.g. in the prevention and treatment of viral infections and cancer. L'invention concerne des hétérodimères de variant d'IL-2 (IL-2v) à demi-vie sérique prolongée ayant une liaison réduite à la sous-unité IL2Rα (CD25). En particulier, l'invention concerne des hétérodimères de Fc-IL -2v et des méthodes de fabrication et d'utilisation, par exemple d'amélioration d'une réponse immunitaire, par exemple dans la prévention et le traitement d'infections virales et du cancer.
Bibliography:Application Number: WO2021US55877